Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
== Publications == Marley, Christopher (September 1, 2008). Pheromone: The Insect Artwork of Christopher Marley. Pomegranate Communications. ISBN 978-0764946196. Marley, Christopher (April 14, 2015). Biophilia. Harry N. Abrams. ISBN 978-1419715617. Marley, Christopher (January 1, 2023). Exquisite Creatures: A Dialogue with Art, Nature, and Science. Christopher Marley Studio. ISBN 979-8986360805.
Argon (18Ar) has 26 known isotopes, from 29Ar to 54Ar, of which three are stable (36Ar, 38Ar, and 40Ar). On Earth, 40Ar makes up 99.6% of natural argon. The longest-lived radioactive isotopes are 39Ar with a half-life of 302 years, 42Ar with a half-life of 32.9 years, and 37Ar with a half-life of 35.01 days. All other isotopes have half-lives of less than two hours, and most less than one minute. Isotopes lighter than 38Ar decay to chlorine or lighter elements, while heavier ones beta decay to potassium. The naturally occurring 40K, with a half-life of 1.248×109 years, decays to stable 40Ar by electron capture (10.72%) and by positron emission (0.001%), and also to stable 40Ca via beta decay (89.28%). These properties and ratios are used to determine the age of rocks through potassium–argon dating. Despite the trapping of 40Ar in many rocks, it can be released by melting, grinding, and diffusion. Almost all argon in the Earth's atmosphere is the product of 40K decay, since 99.6% of Earth's atmospheric argon is 40Ar, whereas in the Sun and presumably in primordial star-forming clouds, argon consists of ~85% 36Ar, ~15% 38Ar and only trace 40Ar. Similarly, the ratio of the isotopes 36Ar:38Ar:40Ar in the atmospheres of the outer planets is measured to be 8400:1600:1. In the Earth's atmosphere, radioactive 39Ar (and to a lesser extent 37Ar) is made by cosmic ray activity, primarily from 40Ar.
=== Fermentation-produced chymosin === Because of the above imperfections of microbial and animal rennets, many producers sought other replacements of rennet. With genetic engineering it became possible to isolate rennet genes from animals and introduce them into certain bacteria, fungi, or yeasts to make them produce recombinant chymosin during fermentation. The genetically modified microorganism is killed after fermentation and chymosin isolated from the fermentation broth, so that the fermentation-produced chymosin (FPC) used by cheese producers does not contain a GMO or any GMO DNA. FPC is identical to chymosin made by an animal, but is produced in a more efficient way. FPC products have been on the market since 1990 and, because the quantity needed per unit of milk can be standardized, are commercially viable alternatives to crude animal or plant rennets, as well as generally preferred to them in industrial production. Originally created by biotechnology company Pfizer, FPC was the first artificially-produced enzyme to be registered and allowed by the US Food and Drug Administration. In 1999, about 60% of US hard cheeses were made with FPC, which thereafter made up to 80% of the global market share for rennet. By 2017, FPC had 90% of the global market share for rennet. By 2021, animal rennet still found use in some traditional or designated European cheeses but FPC covered 80-90% of the market in the US and UK. The most widely used FPC is produced either by the fungus Aspergillus niger and commercialized under the trademark CHY-MAX by the Danish company Chr.
On January 26, 2016, Kennedy launched a third bid for a Senate seat. In seeking to succeed the retiring Vitter, he faced more than 20 opponents. Vitter had announced his forthcoming retirement from the Senate in 2015 after losing a bid for governor to John Bel Edwards. Kennedy's senatorial campaign was endorsed by the U.S. Chamber of Commerce, the National Federation of Independent Business, the NRA Political Victory Fund, the National Right to Life Committee, the American Conservative Union, Vice President-elect Mike Pence and President-elect Donald Trump. Kennedy, who had supported Vitter for governor the previous year, won the jungle primary and faced Democrat Foster Campbell in a December 10 runoff election. President-elect Donald Trump—who had received Kennedy's support in the 2016 presidential election—campaigned for Kennedy the day before the runoff. Kennedy defeated Campbell by 536,204 votes (61%) to 347,813 (39%). He lost the most-populated parishes of Orleans and East Baton Rouge, in which he had been reared, but was a runaway winner in Campbell's home parish of Bossier.
In the spring of 1778, a heavy chain supported by huge log rafts was stretched across the Hudson from West Point to Constitution Island to impede the movement of British ships north of West Point. A second log boom (resembling a ladder in construction) spanned the river about 100 yards (90 m) downstream to absorb the impact of any ship attempting to breach the barrier. The Hudson River's changing tides, strong current, and frequently unfavorable winds created adverse sailing conditions at West Point. Compounding this, the river's narrow width and sharp "S-Curve" there forced any large ship to tack in order to navigate it. Cannon were placed in forts and artillery batteries on both sides of the river to attack ships when they were slowed to a halt by the Patriot barrier placed there. The chain was constructed over six weeks at the Sterling Iron Works in Warwick, Orange County. The multiple forge-fire site and trip hammer was rediscovered in 2008 within Sterling Forest State Park. When completed, the 600-yard (550 m) chain contained iron links two feet (0.6 m) in length, weighing 140 to 180 pounds (64 to 82 kg). The links were carted to New Windsor, where they were put together and floated down the river to West Point on logs late in April. Including swivels, clevises, and anchors, the chain weighed 65 tons. For buoyancy, logs were cut into 16-foot (5 m) lengths, waterproofed, and joined by fours into rafts fastened to one another with 12-foot (3.7 m) timbers.
Sources: en.wikipedia.org
=== Normal tissue structure and wound response === Normal tissues consist of parenchymal cells and stromal cells. The parenchymal cells are the functional units of an organ. In contrast, the stromal cells provide the structure of the organ and secrete extracellular matrix as supportive, connective tissue. In normal epithelial tissues, epithelial cells, or parenchymal cells of epithelia, are highly organized, polar cells. These cells are separated from stromal cells by a basement membrane that prevents these cell populations from mixing. A mixture of these cell types is recognized, normally, as a wound, as in the example of a cut to the skin. Metastasis is an example of a disease state in which a breach of the basement membrane barrier occurs.
However, the reduction of seizure threshold could be attributed to tramadol's putative inhibition of GABAA receptors at high doses (significant inhibition at 100 μM). In addition, desmetramadol is a high-affinity ligand of the DOR, and activation of this receptor could be involved in tramadol's ability to provoke seizures in some individuals, as DOR agonists are well known for inducing seizures. Nausea and vomiting caused by tramadol are thought to be due to activation of the 5-HT3 receptor via increased serotonin levels. In accordance, the 5-HT3 receptor antagonist ondansetron can be used to treat tramadol-associated nausea and vomiting. Tramadol and desmetramadol themselves do not bind to the 5-HT3 receptor.
Recombinant human parathyroid hormone is an artificially manufactured form of the parathyroid hormone used to help treat hypoparathyroidism (under-active parathyroid glands) and osteoporosis. Recombinant human parathyroid hormone (Preotact) received market authorization in the European Union in April 2006 to treat osteoporosis in postmenopausal women at high risk of fractures. Preotact marketing authorisation was later voluntarily withdrawn in 2014 by the holder NPS Pharma. FDA approval (as Preos) was not granted in the US for the same indication due to hypercalcemia and injection device issues. Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and received (as Natpar) conditional market authorization in the European Union in February 2017 as orphan drug. On 2019 Natpara was recalled in the US due to rubber particle issues emerging from daily use of the cartridge. Takeda announced in 2022 its decision to stop manufacturing Natpara/Natpar globally at the end of 2024.
Larry Hama took over Wolverine's solo series in 1990, and exerted a major influence on how Wolverine was depicted throughout the X-Men family of publications during his run. Hama commented that he "considered the Chris Claremont, Frank Miller, and Barry Windsor-Smith [Wolverine] stories to be canon" and "pretty much ignored everything else." From 1990 to 1992, the series was usually illustrated by Marc Silvestri, who contributed to the character's rising popularity; his work on Wolverine also established him as a star artist in the industry. In issues #48-50 (November 1991-January 1992), Hama delved into Wolverine's mysterious past in the Weapon X program, which was often highly convoluted and unreliable due to the false memories implanted by the program's designers. In 1992, he revisited the Japanese setting and characters of Claremont's and Miller's earlier limited series, ending the story with the poisoning of Mariko Yashida, Logan's lover, and her mercy killing at the hands of Wolverine. During the Fatal Attractions storyline, in X-Men #25 (October 1993), the adamantium in Wolverine's body is ripped out by Magneto, using his magnetic abilities. Writers Fabian Nicieza and Scott Lobdell were inspired by a suggestion of another Marvel writer, Peter David. The story arc reveals that Wolverine has natural bone claws, in contrast to previously established narrative continuity that his claws were entirely bionic. Wolverine himself is confused by this realization, and his healing factor is also greatly weakened by recovery from this extraordinary injury.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.